The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Export

@article{citeulike:739827, abstract = {The cell cycle is controlled by numerous mechanisms ensuring correct cell division. This review will focus on these mechanisms, i.e. regulation of cyclin-dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events. The quality checkpoints activated after DNA damage are also discussed. The complexity of the regulation of the cell cycle is also reflected in the different alterations leading to aberrant cell proliferation and development of cancer. Consequently, targeting the cell cycle in general and CDK in particular presents unique opportunities for drug discovery. This review provides an overview of deregulation of the cell cycle in cancer. Different families of known CDK inhibitors acting by ATP competition are also discussed. Currently, at least three compounds with CDK inhibitory activity (flavopiridol, UCN-01, roscovitine) have entered clinical trials.}, address = {Faculty of Medicine, Laboratory of Experimental Hematology, University of Antwerp, Antwerp University Hospital, Edegem, Belgium.}, author = {Vermeulen, K. and Van Bockstaele, D. R. and Berneman, Z. N.}, citeulike-article-id = {739827}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/12814430}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=12814430}, issn = {0960-7722}, journal = {Cell Prolif}, keywords = {anticancer, cell-cycle}, month = {June}, number = {3}, pages = {131--149}, posted-at = {2006-07-05 09:31:10}, priority = {2}, title = {The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12814430}, volume = {36}, year = {2003} }

TY - JOUR ID - citeulike:739827 L3 - citeulike-article-id:739827 N2 - The cell cycle is controlled by numerous mechanisms ensuring correct cell division. This review will focus on these mechanisms, i.e. regulation of cyclin-dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events. The quality checkpoints activated after DNA damage are also discussed. The complexity of the regulation of the cell cycle is also reflected in the different alterations leading to aberrant cell proliferation and development of cancer. Consequently, targeting the cell cycle in general and CDK in particular presents unique opportunities for drug discovery. This review provides an overview of deregulation of the cell cycle in cancer. Different families of known CDK inhibitors acting by ATP competition are also discussed. Currently, at least three compounds with CDK inhibitory activity (flavopiridol, UCN-01, roscovitine) have entered clinical trials. IS - 3 JF - Cell Prolif SN - 0960-7722 AD - Faculty of Medicine, Laboratory of Experimental Hematology, University of Antwerp, Antwerp University Hospital, Edegem, Belgium. EP - 149 TI - The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. VL - 36 SP - 131 KW - anticancer KW - cell-cycle AU - Vermeulen, K AU - Van Bockstaele, DR AU - Berneman, ZN PY - 2003/06// UR - http://view.ncbi.nlm.nih.gov/pubmed/12814430 ER -